Xenon Pharmaceuticals (XENE) Capital Expenditures (2013 - 2026)
Xenon Pharmaceuticals' (XENE) quarterly Capital Expenditures came in at $133000.0 in Q1 2026, up 209.3% year-on-year from $43000.0 in Q1 2025, and down 58.18% on a QoQ basis from $318000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Capital Expenditures (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Capital Expenditures data on file, last reported at $133000.0 in Q1 2026.
- On a quarterly basis, Capital Expenditures rose 209.3% year-over-year to $133000.0 in Q1 2026; TTM through Mar 2026 was $889000.0, a 69.66% decrease from a year earlier, with the FY2025 full-year figure at $799000.0, down 74.02% from the prior year.
- Capital Expenditures for Q1 2026 stood at $133000.0, down from $318000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for XENE reached as high as $2.2 million in Q1 2023 and fell as low as $43000.0 in Q1 2025.
- Historically, Capital Expenditures has averaged $736352.9 across 5 years, with a median of $386000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 940.57% in 2023 and fell as far as 95.55% in 2023.
- Year by year, Capital Expenditures stood at $1.8 million in 2022, then plunged by 95.55% to $78000.0 in 2023, then jumped by 903.85% to $783000.0 in 2024, then plunged by 59.39% to $318000.0 in 2025, then plunged by 58.18% to $133000.0 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $133000.0 in Q1 2026, $318000.0 in Q4 2025, and $281000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Xenon Pharmaceuticals | 5.71 Bn | 5.71 Bn | - | 133,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 133,000.00 |
| Mar 31, 2026 | 133,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 188,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Dec 31, 2023 | 78,000.00 |